Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W I Cox

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The Journal of Infectious Diseases|August 7, 1999
A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)S P Adler, S A Plotkin, E Gonczol, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
The Journal of Infectious Diseases|July 9, 1999
Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in childrenH M Spiegel, E DeFalcon, G S Ogg, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The Journal of Infectious Diseases|August 7, 1999
A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)S P Adler, S A Plotkin, E Gonczol, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
The Journal of Infectious Diseases|July 9, 1999
Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in childrenH M Spiegel, E DeFalcon, G S Ogg, et al.
AIDS (London, England)|January 6, 1999
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation GroupR B Belshe, G J Gorse, M J Mulligan, et al.
Pageof 4